Combining the power of CRISPR technology and cell therapy, scientists are expediting their search for more effective and safer CAR T cell therapies. However, the CAR knock-in efficiency in human primary T cells may not be ideal yet, even with the most advanced ribonucleoprotein (RNP) and electroporation delivery method. This week, a study published in Nature Biotechnology suggested a novel approach that improves large gene insertion efficiency in primary cells by 2-6 folds.
